Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Tóm tắt
Từ khóa
Tài liệu tham khảo
Alexander, 2003, NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older, Diabetes, 52, 1210, 10.2337/diabetes.52.5.1210
2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143
Haffner, 1998, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N Engl J Med, 339, 229, 10.1056/NEJM199807233390404
Booth, 2006, Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study, Lancet, 368, 29, 10.1016/S0140-6736(06)68967-8
Scheen, 2003, Current management strategies for coexisting diabetes mellitus and obesity, Drugs, 63, 1165, 10.2165/00003495-200363120-00001
Yusuf, 2005, Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: case-control study, Lancet, 366, 1640, 10.1016/S0140-6736(05)67663-5
Chan, 1994, Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men, Diabetes Care, 17, 961, 10.2337/diacare.17.9.961
Wing, 1987, Type II diabetic subjects lose less weight than their overweight nondiabetic spouses, Diabetes Care, 10, 563, 10.2337/diacare.10.5.563
Howlett, 2004, Cannabinoid physiology and pharmacology: 30 years of progress, Neuropharmacology, 47, 345, 10.1016/j.neuropharm.2004.07.030
Di Marzo, 2001, Leptin-regulated endocannabinoids are involved in maintaining food intake, Nature, 410, 822, 10.1038/35071088
Ravinet Trillou, 2003, Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice, Am J Physiol Regul Integr Comp Physiol, 284, R345, 10.1152/ajpregu.00545.2002
Poirier, 2005, The anti-obesity effect of rimonabant is associated with an improved serum lipid profile, Diabetes Obes Metab, 7, 65, 10.1111/j.1463-1326.2004.00374.x
Bensaid, 2003, The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells, Mol Pharmacol, 63, 908, 10.1124/mol.63.4.908
Osei-Hyiaman, 2005, Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity, J Clin Invest, 115, 1298, 10.1172/JCI200523057
Liu, 2005, Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice, Int J Obes Relat Metab Disord, 29, 183, 10.1038/sj.ijo.0802847
Matias, 2006, Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia, J Clin Endocrinol Metab, 91, 3171, 10.1210/jc.2005-2679
Van Gaal, 2005, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, Lancet, 365, 1389, 10.1016/S0140-6736(05)66374-X
Pi-Sunyer, 2006, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial, JAMA, 295, 761, 10.1001/jama.295.7.761
Després, 2005, Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia, N Engl J Med, 353, 2121, 10.1056/NEJMoa044537
Matthews, 1985, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007/BF00280883
Ware, 1992, The MOS 36-item short-form health survey (SF-36), Med Care, 30, 473, 10.1097/00005650-199206000-00002
Kolotkin, 2001, Development of a brief measure to assess quality of life in obesity, Obes Res, 9, 102, 10.1038/oby.2001.13
Kolotkin, 2002, Psychometric evaluation of the Impact Of Weight On Quality Of Life-Lite Questionnaire (IWQOL-Lite) in a community sample, Quality of Life Research, 11, 157, 10.1023/A:1015081805439
Hill, 1995, Techniques for the experimental measurement of human being behaviour and food intake: a practical guide, Int J Obes Relat Metab Disord, 19, 361
Zigmond, 1983, The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, 361, 10.1111/j.1600-0447.1983.tb09716.x
Hochberg, 1988, A sharper Bonferonni procedure for multiple tests of significance, Biometrika, 75, 800, 10.1093/biomet/75.4.800
Gadbury, 2003, Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF, Obes Rev, 4, 175, 10.1046/j.1467-789X.2003.00109.x
Wood, 2005, Comparison of imputation and modelling methods in the analysis of a physical activity trial with missing outcomes, Int J Epidemiol, 34, 89, 10.1093/ije/dyh297
Buyse, 1998, Criteria for the validation of surrogate endpoints in randomized experiments, Biometrics, 54, 1014, 10.2307/2533853
American Diabetes Association, 2005, Clinical practice recommendations 2005, Diabetes Care, 28, S1
Stratton, 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ, 321, 405, 10.1136/bmj.321.7258.405
DeFronzo, 2005, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes, Diabetes Care, 28, 1092, 10.2337/diacare.28.5.1092
Gaede, 2003, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes, N Engl J Med, 348, 383, 10.1056/NEJMoa021778
Stumvoll, 2005, Type 2 diabetes: principles of pathogenesis and therapy, Lancet, 365, 1333, 10.1016/S0140-6736(05)61032-X
Danesh, 2004, C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, N Engl J Med, 350, 1387, 10.1056/NEJMoa032804
Cota, 2003, The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis, J Clin Invest, 112, 423, 10.1172/JCI17725
Chandran, 2003, Adiponectin: more than just another fat cell hormone?, Diabetes Care, 26, 2442, 10.2337/diacare.26.8.2442
Sattar, 2006, Adiponectin and coronary heart disease: a prospective study and meta-analysis, Circulation, 114, 623, 10.1161/CIRCULATIONAHA.106.618918
Williamson, 2000, Intentional weight loss and mortality among overweight individuals with diabetes, Diabetes Care, 23, 1499, 10.2337/diacare.23.10.1499
Guare, 1995, Comparison of obese NIDDM and nondiabetic women: short- and long-term weight loss, Obes Res, 3, 329, 10.1002/j.1550-8528.1995.tb00158.x
Anon, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6
2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512
Wing, 1987, Long-term effects of modest weight loss in type II diabetic patients, Arch Intern Med, 147, 1749, 10.1001/archinte.1987.00370100063012
Nathan, 2006, Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 29, 1963, 10.2337/dc06-9912
Norris, 2004, Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis, Arch Intern Med, 164, 395, 10.1001/archinte.164.13.1395